Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT132 in Moderate to Severe Rheumatoid Arthritis
CTR20170265Phase 2Active
- Sponsor
- Livzon Monoclonal Antibody
- Start
- Mar 2017
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Resamirigene bilparvovec in rheumatoid arthritis (RA), sponsored by Livzon Monoclonal Antibody. Started Mar 2017; status: active.
02
Drugs
Resamirigene bilparvovec
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20170265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170265.